Our healthcare law firm works with many providers and healthcare practices who are facing an investigation from the Drug Enforcement Administration (DEA). This blog covers recent enforcement trends where the DEA has been investigating ketamine sellers that sell ketamine for at-home use. If you are being investigated by the DEA, the DEA has approached your practice, or you would like to discuss this blog post, you may contact our healthcare law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.
As we have discussed in prior blog posts, ketamine has been administered off-label to treat patients with treatment-resistant depression, and ketamine has gained popularity recently as a possible treatment option for treatment-resistant depression. Ketamine is a schedule III controlled substance, so ketamine is within the DEA’s and the Food and Drug Administration (FDA)’s purview. In June and July 2026, the FDA sent warning letters to several online sellers of ketamine. The warning letters state these online ketamine sellers are selling non-FDA-approved, misbranded ketamine products and are putting consumers at serious risk of harm. The DEA has been investigating whether at-home ketamine use and telehealth appointments used to prescribe ketamine are medically necessary. If the DEA finds merit to these investigations, the DEA can impose severe penalties, including revoking a provider’s DEA registration. The investigations are ongoing, and our Firm will continue to monitor developments into these investigations.
If you are being investigated by the DEA, the DEA has approached your practice, or would like to discuss this blog post, you may contact our healthcare law firm at (404) 685-1662 (Atlanta) or (706) 722-7886 (Augusta), or by email, info@littlehealthlaw.com. You may also learn more about our law firm by visiting www.littlehealthlaw.com.
Little Health Law Blog

